Sign In
Free Newsletter
Sun Pharma to acquire Merck spinoff Organon for $11.75B
The addition by India’s largest pharmaceutical company of the women's health-focused Merck spinoff will expand the buyer's global pharma footprint in that space and specialty medicines.
Trump 100% pharma tariffs raise concerns for New Jersey life sciences (updated)
The president's levies on imported drugs and ingredients raise concerns for New Jersey’s life sciences sector, with risks to costs and innovation.
HINJ forum highlights NJ life sciences, innovation economy
Featuring Gov. Mikie Sherrill and others, the forum showcased the state's life sciences leadership, connecting industry, policymakers and researchers to drive innovation and economic growth.
Ferring to cut 64 jobs at Parsippany HQ amid global layoffs
The layoffs from Ferring Pharmaceuticals come as part of a larger plan to eliminate 500 positions worldwide and streamline operations.
Novartis’ $12B Avidity acquisition to expand neuroscience pipeline
The play for San Diego-based Avidity Biosciences will add RNA therapeutics that target rare genetic neuromuscular diseases.
Celltrion pays $330M for Eli Lilly plant to avoid tariffs, boost output
The play will expand the Korean biopharma's U.S. production, while strengthening New Jersey's life sciences footprint – particularly in Somerset County.
CorMedix completes $300M acquisition of Melinta Therapeutics
The combination of the New Jersey-based firms adds the target's seven marketed products to the buyer's portfolio, expanding its biopharma growth platform.
ProBio opens cell, gene therapy hub in Hopewell
Located at the Princeton West Innovation Campus, the new 128,000-square-foot facility will create more than 110 high-skilled jobs.
Bristol Myers Squibb plans 4th round of 2025 NJ layoffs (updated)
Marking its fourth round of cuts this year in the state, the company will eliminate dozens of jobs in a move tied to a $2 billion cost-cutting initiative.
Hepion names new interim CEO, shifts to diagnostic innovation
Dr. Kaouthar Lbiati will now lead the biopharmaceutical company, which previously focused on treatments for chronic liver diseases.
Rare disease specialist Insmed continues rapid growth in NJ (updated)
NJBIZ recently caught up with CEO Will Lewis to discuss the Bridgewater-based biopharmaceutical company's latest happenings and milestones, what’s on the horizon and more.
Following restructuring, Hepion to merge with Israeli pharma firm
In December 2023, the Edison-based pharmaceutical company initiated a plan aimed at preserving capital, starting with cutting operating costs by about 60%.
